Progress forecasts FY2026 EPS of $6.09-$6.21 while targeting net leverage of ~2.8x (NASDAQ:PRGS)July 1, 2026
Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market (OTCMKTS:ELTP)June 30, 2026
Share Facebook Twitter LinkedIn Pinterest Email RH projects 10% to 13% revenue growth for fiscal 2025 with strategic product expansion
Progress forecasts FY2026 EPS of $6.09-$6.21 while targeting net leverage of ~2.8x (NASDAQ:PRGS)July 1, 2026
Elite Pharmaceuticals outlines ropinirole launch next month and targets 5% to 10% of its $12M market (OTCMKTS:ELTP)June 30, 2026
By Press Room
By Press Room
By Press Room
